Top Hyaluronic Acid (HA) Filler Brand Guide

Hyaluronic Acid (HA) Fillers List Overview

Hyaluronic Acid (HA) fillers add and restore facial volume. They are popular for aesthetic treatments due to their biocompatibility and effectiveness in addressing various skin concerns.

To help you compare HA filler brands, here is a summary of the main HA filler products on the market, along with the pharma company behind them, their FDA approval date, their basic characteristics and approved uses as of 2023. While we did our best to summarize the products on the market, please consult directly with the Pharma company and or a qualified medical professional before considering treatment.

At Pinch, we use two dermal fillers including Belotero Balance and Versa depending on the Pinch Provider and your med spa treatment goals.

BELOTERO Balance®

Name: BELOTERO Balance®
Pharma Company: Merz
FDA Approval Date: November 2011
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 22.5 mg/mL.
Approved Uses: For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds.

Juvéderm® Ultra XC

Name: Juvéderm® Ultra XC
Pharma Company: Allergan Aesthetics, an AbbVie Company
FDA Approval Date: June 2006
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 24 mg/mL.
Approved Uses: For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. Also indicated for injection into the lips and perioral area for lip augmentation.

Juvéderm® Voluma® XC

Name: Juvéderm® Voluma® XC
Pharma Company: Allergan Aesthetics, an AbbVie Company
FDA Approval Date: October 2013
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20 mg/mL.
Approved Uses: For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. Approved for mid-face injection via a STERiGLIDE™ cannula (9/2019). Also approved for augmentation of the chin region to improve the chin profile in adults over the age of 21 (6/2020).

Juvéderm® Volux™ XC

Name: Juvéderm® Volux™ XC
Pharma Company: Allergan Aesthetics, an AbbVie Company
FDA Approval Date: August 2022
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 25 mg/mL.
Approved Uses: For subcutaneous and/or supraperiosteal injection for improvement in jawline definition in adults over the age of 21.

Juvéderm® Volbella® XC

Name: Juvéderm® Volbella® XC
Pharma Company: Allergan Aesthetics, an AbbVie Company
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 15 mg/mL.
Approved Uses: For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. For use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. For the improvement of infraorbital hollowing in adults over the age of 21.

Juvéderm® Vollure® XC

Name: Juvéderm® Vollure® XC
Pharma Company: Allergan Aesthetics, an AbbVie Company
FDA Approval Date: March 2017
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 17.5 mg/mL.
Approved Uses: For deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. For the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds in adults over the age of 21.

Restylane® Lyft

Name: Restylane® Lyft
Pharma Company: Galderma
FDA Approval Date: February 2010
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing lidocaine 0.3%. Total HA concentration: 20 mg/mL. Particle size range: 750-1000 µm.
Approved Uses: For implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds. For subcutaneous to supraperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients over the age of 21. For injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21.

Restylane® Defyne

Name: Restylane® Defyne
Pharma Company: Galderma
FDA Approval Date: December 2016
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL.
Approved Uses: For injection into the mid-to-deep dermis for correction of moderate to severe, deep facial wrinkles and folds such as nasolabial folds in patients over the age of 21. Also approved for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21 (2/2021).

Restylane® Kysse

Name: Restylane® Kysse
Pharma Company: Galderma
FDA Approval Date: May 2020
Characteristics: Bacteria-based HA filler, cross linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20mg/mL. Moderate lifting capacity.
Approved Uses: For injection into the lips for lip augmentation and the correction of upper perioral rhytids in patients over the age of 21.

Restylane® Contour

Name: Restylane® Contour
Pharma Company: Galderma
FDA Approval Date: June 2021
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL.
Approved Uses: For use in cheek augmentation and for the correction of midface contour deficiencies in adults over the age of 21.

Restylane®/Restylane®-L

Name: Restylane®/Restylane®-L
Pharma Company: Galderma
FDA Approval Dates: December 2003 for Restylane®, October 2011 for Restylane®-L
Characteristics: Bacteria-based HA filler, cross-linked with BDDE. Total HA concentration: 20 mg/mL. Particle size range: 330-430 µm. Restylane-L contains 0.3% lidocaine.
Approved Uses: For injection into the mid to deep dermis for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Also indicated for submucosal implantation for lip augmentation in patients over the age of 21.

Restylane® Silk

Name: Restylane® Silk
Pharma Company: Galderma
FDA Approval Date: June 2014
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA Concentration: 20 mg/mL; Particle size range: 50–220 µm.
Approved Uses: For submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

Restylane® Refyne

Name: Restylane® Refyne
Pharma Company: Galderma
FDA Approval Date: December 2016
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 20.0 mg/mL; Restylane Refyne is less crosslinked than Restylane Defyne.
Approved Uses: For injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds such as nasolabial folds in patients over the age of 21.

Revanesse® Versa

Name: Revanesse® Versa
Pharma Company: Prollenium US
FDA Approval Date: April 2017
Characteristics: Bacteria-based HA filler, cross-linked with BDDE. Total HA concentration: 25 mg/mL.
Approved Uses: For injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds in adults aged 22 years or older.

Revanesse® Lips

Name: Revanesse® Lips
Pharma Company: Prollenium US
FDA Approval Date: September 2020
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 22-28 mg/mL.
Approved Uses: For submucosal implantation for lip augmentation in patients 22 years of age or older.

RHA® 2

Name: RHA® 2
Pharma Company: Revance Therapeutics, Inc.
FDA Approval Date: October 2017
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g.
Approved Uses: For injection in the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults aged 22 years or older.

RHA® 3

Name: RHA® 3
Pharma Company: Revance Therapeutics, Inc.
FDA Approval Date: October 2017
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g.
Approved Uses: Similar to RHA® 2, for injection in the mid-to-deep dermis targeting moderate to severe dynamic facial wrinkles and folds.

RHA® 4

Name: RHA® 4
Pharma Company: Revance Therapeutics, Inc.
FDA Approval Date: October 2017
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 23 mg/g.
Approved Uses: For injection into the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults aged 22 years or older.

RHA® Redensity

Name: RHA® Redensity
Pharma Company: Revance Therapeutics, Inc.
FDA Approval Date: October 2022
Characteristics: Bacteria-based HA filler, cross-linked with BDDE, containing 0.3% lidocaine. Total HA concentration: 15 mg/mL.
Approved Uses: For injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults aged 22 years or older.

Other Types Of Filler

As the medical spa market grows additional products will emerge. Currently, there are also permanent fillers and biostimulatory fillers that may be right for some clients although they are not something Pinch currently offers on our platform.

As clinician looking to learn more about filler, we recommend reaching out to the respective Pharma company who makes the products you are interested in. If you are potential client looking to better understand HA filler treatment options, we'd welcome you do book a consult with an aesthetic nurse practitioner from Pinch.
‍